LPL Financial
APRE icon

LPL Financial’s Aprea Therapeutics APRE Stock Holding History

LPL Financial’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$14.3K Buy
19,052
+3,000
+19% +$2.18K ﹤0.01% 6249
2026
Q2 		$12.9K Sell
16,052
-5,000
-24% -$4.17K ﹤0.01% 6153
2026
Q1 		$16.1K Sell
21,052
-5,000
-19% -$3.93K ﹤0.01% 5893
2025
Q4 		$22.2K Buy
26,052
+10,000
+62% +$12.3K ﹤0.01% 5802
2025
Q3 		$23.7K Sell
16,052
-1,000
-6% -$1.64K ﹤0.01% 5725
2025
Q2 		$28.8K Buy
17,052
+1,000
+6% +$1.7K ﹤0.01% 5427
2025
Q1 		$32.7K Hold
16,052
– – ﹤0.01% 5204
2024
Q4 		$52.8K Buy
+16,052
New +$53.6K ﹤0.01% 5097

Other funds holding APRE

ACM
AIGH Capital Management Baltimore, Maryland $992M AUM 516.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
TD Waterhouse Canada
TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

LPL Financial's APRE Position: Q3 2026 in Review

LPL Financial increased its Aprea Therapeutics (APRE) stake by 19% in Q3 2026, buying an estimated $2.18K and bringing the position to 19,052 shares worth $14.3K. The position accounts for ﹤0.01% of the portfolio, ranked #6249.

LPL Financial first reported a position in APRE in Q4 2024 and has held it in 8 quarters since. The position peaked at $52.8K in Q4 2024. 6 funds tracked by Wall St. Rank hold APRE as of Q3 2026.

  • LPL Financial held 19,052 shares of Aprea Therapeutics worth $14.3K as of Q3 2026.
  • LPL Financial bought 3,000 Aprea Therapeutics shares in Q3 2026, an estimated $2.18K.
  • Aprea Therapeutics made up ﹤0.01% of LPL Financial's portfolio in Q3 2026, its #6249 holding.
  • LPL Financial first reported a position in Aprea Therapeutics in Q4 2024 and has held it in 8 quarters since.
  • LPL Financial's Aprea Therapeutics position peaked at $52.8K in Q4 2024.
  • 6 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q3 2026.

Based on LPL Financial's 13F filing for Q3 2026, filed 6 Nov 2026.